Skip to main content

Table 8 Distribution and clinical characteristcs of the COEUR cases per Canadian province

From: Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

 

Location of tumor bank

Quebec

Ontario

Manitoba

Alberta

British Columbia

Total

Total cases

976

330

242

17

479

2046

Histotype

BOT

9

4

7

0

3

23

HGSC

603

199

120

10

314

1246

EC

132

56

31

3

73

295

LGSC

52

24

19

0

8

103

CCC

123

37

36

1

62

259

MC

43

1

28

2

14

88

other

14

8

1

1

4

29

Age (mean years)a

at diagnosis

63

60

61

61

62

62

at end of follow-up

66

64

65

66

66

65

Year of diagnosis (range)

 

1992–2015

1996–2013

2012–2015

1998–2015

1998–2013

1992–2015

Follow-up (mean, months)

 

54(0–270)

51(0–168)

32(9–49)

49(0–181)

47(0–173)

48(0–270)

Survival ratea

Disease specific survival

30%

41%

73%

36%

29%

33%

5-years survival rate

31%

40%

NA

42%

33%

34%

Long Term Survival rate [> 10 years]

9%

7%

NA

12%

6%

8%

Treatment type

none

47

5

55

0

23

130

carboplatin+taxol

690

238

160

15

351

1454

cisplatin+taxol

40

28

9

0

20

97

platinum

21

21

15

0

45

102

platinum+other

47

2

1

0

6

56

taxol

3

0

0

0

0

3

other

15

6

0

0

1

22

Total

863

300

240

15

446

1864

% response to treatmenta

69%

84%

90%

91%

71%

75%

BRCA mutation carrier status

non carriers

306

27

6

9

137

485

carriers

58

16

2

4

33

113

total

370

33

8

13

170

594

% carriers

16%

48%

25%

31%

19%

19%

  1. NA non applicable, BOT borderline tumor, HGSC High-Grade Serous Carcinoma, EC Endometrioid Carcinoma, LGSC Low-Grade Serous Carcinoma, CCC Clear Cell Carcinoma, MC Mucinous Carcinoma
  2. a HGSC patients only